• Oklahoma State rejects anthrax study over euthanasia of primates

    The U.S. National Institutes of Health wanted OSU to conduct research on treatment for anthrax; the study involves baboons, which must be destroyed after anthrax exposure to ensure they do not infect others; In April, OSU announced that animals will no longer be euthanized in teaching labs at the veterinary school; measure was the result of pressure by Madeleine Pickens, the wife of billionaire benefactor and OSU alumnus T. Boone Pickens

  • Experts call for changes in U.S. vaccine creation process

    The current U.S. vaccine-manufacturing plan was developed prior to the cold war, and has never been updated; currently, the United States grows its vaccines in eggs over the course of six to eight months, and as there has been no real financial incentive to upgrade the vaccine making process, pharmaceutical manufacturers have instead focused on more profitable medications rather than vaccines

  • Governments worry about more cases of drug-resistant H1N1

    Health officials in the United Kingdom and the United States report the likely person-to-person spread of a drug-resistant strain of H1N1; most patients thus far infected with the strain have already been immune-deficient

  • Gene synthesis companies establish measures to counter bioterrorism

    The five largest synthetic DNA companies will establish common security measures to prevent the use of synthetic DNA by bioterrorists; among other things, the “Harmonized Screening Protocol” will screen gene sequences against a regulated pathogen database

  • Anticipating new diseases, bioterror methods

    The 150 researchers at the University of Florida’s Emerging Pathogens Institute work to anticipate and respond to new diseases and old ones — such as tuberculosis and cholera — that can turn into new threats or make a comeback

  • UIC to develop antibiotics against potential bioterrorism agents

    The University of Illinois at Chicago receives $4 million in stimulus package funds to develop new antibiotics to treat anthrax, tularemia and plague

  • NIAID allocated $208 million to fight emerging infectious diseases from bioterrorism

    Using its own research funds, augmented by stimulus package money, NIH awarded $208 million to two programs that support research better to understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism

  • SRI opens Virginia facility

    SRI International opened a new facility for its Center for Advanced Drug Research (CADRE); scientists at the new facility will work on developing vaccines, more quickly diagnosing infections, and developing new treatments

  • Soldier in Afghanistan dies of Ebola-like virus infection

    Rare virus poses new threat to troops; on 16 September an American soldier died from what turned out to be Crimean-Congo hemorrhagic fever after he was bitten by a tick